Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia

Cancer Science

Volumn 100, Issue 8, 2009, Pages 1366-1373

  Kizaka Kondoh, Shinae ^a   Konse Nagasawa, Hideko ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,1,1,3,3,3 HEXAFLUORO 2 PROPOXY) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; AROMATIC NITRO COMPOUND; COPPER 64; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINE 123; IODINE 124; MISONIDAZOLE; MOLECULAR MARKER; NITROREDUCTASE; PIMONIDAZOLE;

AUTORADIOGRAPHY; CANCER GROWTH; CELL HYPOXIA; CELL LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BINDING; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MOLECULAR MECHANICS; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONCENTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; TUMOR CELL;

ANIMALS; CELL HYPOXIA; DIAGNOSTIC IMAGING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; NITROIMIDAZOLES; OXYGEN;

EID: 67650689649     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01195.x     Document Type: Review

References (81)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Sem Radiat Oncol. 2004; 14: 198-206.
2. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4: 437-47.
3. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
4. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: A target for selective cancer therapy. Cancer Sci. 2003; 94: 1021-8.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-32.
6. Epstein AC, Gleadle JM, McNeill LA et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107: 43-54.
7. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30: 393-402.
8. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol. 2003; 179: 801-11.
9. Semenza GL. VHL and p53: Tumor suppressors team up to prevent cancer. Mol Cell. 2006; 22: 437-9.
10. 2 tension measurements. Cancer Res. 1991; 51: 6098-102.
11. Griffiths JR, Robinson SP. The OxyLite: A fibre-optic oxygen sensor. Br J Radiol. 1999; 72: 627-30.
12. Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 1995; 72: 889-95.
13. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008; 8: 94-107.
14. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 1999; 151: 580-9.
15. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 2005; 65: 7259-66.
16. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: How much, how important? Head Neck. 2005; 27: 622-38.
17. Dubois L, Landuyt W, Haustermans K et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer. 2004; 91: 1947-54.
18. He F, Deng X, Wen B et al. Noninvasive molecular imaging of hypoxia in human xenografts: Comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res. 2008; 68: 8597-606.
19. Janssen HL, Haustermans KM, Sprong D et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2002; 54: 1537-49.
20. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer. 2008; 122: 2726-34.
21. Brown JM. Evidence for acutely hypoxic cells in mouse tumors and a possible mechanism of reoxygenation. Br J Radiol. 1979; 52: 650-6.
22. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995; 22: 265-80.
23. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008; 49 (Suppl 2): 129S-48S.
24. Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke. 2008; 39: 1629-37.
25. Maeda K, Osato T, Umezawa H. A new antibiotic, azomycin. J Antibiot (Tokyo). 1953; 6: 182.
26. Mohindra JK, Rauth AM. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976; 36: 930-6.
27. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother. 1993; 31: 201-10.
28. Nagasawa H, Uto Y, Kirk KL, Hori H. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull. 2006; 29: 2335-42.
29. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 2007; 19: 397-417.
30. Bremner JC. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: With particular reference to in.vivo methods of evaluation. Cancer Metastasis Rev. 1993; 12: 177-93.
31. Denny WA. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol. 2000; 1: 25-9.
32. Jin CZ, Nagasawa H, Shimamura M et al. Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers. Bioorg Med Chem. 2004; 12: 4917-27.
33. Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des. 1998; 13: 687-702.
34. Bolton JL, McClelland RA. Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxyamino) imidazoles. J Am Chem Soc. 1989; 111: 8172-81.
35. Hori H, Nagasawa H, Terada H. Effects of free radicals from hypoxic cell radiosensitizers, hypoxic cell cytotoxins, and bioreductive anticancer drugs on the biological environment, environmental oxidants. In: Nriagu O, Simmons MS, eds. Environmental Oxidants. New York: John Wiley and Sons, 1994: 425-44.
36. Kedderis GL, Miwa GT. The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab Rev. 1988; 19: 33-62.
37. Melo T, Ballinger JR, Rauth AM. Role of NADPH: Cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. Biochem Pharmacol. 2000; 60: 625-34.
38. Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL, Laskin JD. Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008; 44: 1169-79.
39. Skelly JV, Knox RJ, Jenkins TC. Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy. Mini Rev Med Chem. 2001; 1: 293-306.
40. Janssen HL, Hoebers FJ, Sprong D et al. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol. 2004; 70: 91-7.
41. Azuma Y, Chou SC, Lininger RA, Murphy BJ, Varia MA, Raleigh JA. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin. Clin Cancer Res. 2003; 9: 4944-52.
42. Cobb LM, Nolan J, Hacker T. Retention of misonidazole in normal and malignant tissues: Interplay of hypoxia and reductases. Int J Radiat Oncol Biol Phys. 1992; 22: 655-9.
43. Orna MV, Mason RP. Correlation of kinetic parameters of nitroreductase enzymes with redox properties of nitroaromatic compounds. J Biol Chem. 1989; 264: 12 379-84.
44. Adams GE, Flockhart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976; 67: 9-20.
45. Wardman P. Some reactions and properties of nitro radical-anions important in biology and medicine. Environ Health Perspect. 1985; 64: 309-20.
46. Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer. 1995; 61: 567-73.
47. Franko AJ, Koch CJ, Garrecht BM, Sharplin J, Hughes D. Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. Cancer Res. 1987; 47: 5367-76.
48. Workman P, Brown JM. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981; 6: 39-49.
49. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980; 82: 171-90.
50. Watts ME, Jones NR. The effect of extracellular pH on radiosensitization by misonidazole and acidic or basic analogues. Int J Radiat Biol Relat Stud Phys Chem Med. 1985; 47: 645-53.
51. Kleiter MM, Thrall DE, Malarkey DE et al. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys. 2006; 64: 592-602.
52. Bennewith KL, Raleigh JA, Durand RE. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res. 2002; 62: 6827-30.
53. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res. 2007; 167: 127-45.
54. Thrall DE, McEntee MC, Cline JM, Raleigh JA. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation. Int J Radiat Oncol Biol Phys. 1994; 28: 649-59.
55. Azuma C, Raleigh JA, Thrall DE. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res. 1997; 148: 35-42.
56. Ljungkvist AS, Bussink J, Kaanders JH et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys. 2005; 62: 1157-68.
57. Raleigh JA, Koch CJ. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol. 1990; 40: 2457-64.
58. Troost EG, Laverman P, Philippens ME et al. Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging. 2008; 35: 1803-11.
59. Bache M, Kappler M, Said HM, Staab A, Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: Current preclinical and clinical strategies. Curr Med Chem. 2008; 15: 322-38.
60. Evans SM, Fraker D, Hahn SM et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2006; 64: 922-7.
61. Komar G, Seppanen M, Eskola O et al. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008; 49: 1944-51.
62. Yapp DT, Woo J, Kartono A et al. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int. 2007; 99: 1154-60.
63. 2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008; 70: 1202-12.
64. Engelhardt EL, Schneider RF, Seeholzer SH, Stobbe CC, Chapman JD. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. J Nucl Med. 2002; 43: 837-50.
65. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997; 38: 1155-60.
66. Padhani A. PET imaging of tumour hypoxia. Cancer Imaging. 2006; 6: S117-21.
67. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med. 2007; 37: 451-61.
68. Jin GY, Li SJ, Moulder JE, Raleigh JA. Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by 1H/19F magnetic resonance spectroscopy. Int J Radiat Biol. 1990; 58: 1025-34.
69. Procissi D, Claus F, Burgman P et al. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res. 2007; 13: 3738-47.
70. Salmon HW, Siemann DW. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol. 2004; 73: 359-66.
71. 2 sensing. Science. 2001; 292: 464-8.
72. 2-regulated prolyl hydroxylation. Science. 2001; 292: 468-72.
73. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399: 271-5.
74. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 2002; 62: 2013-18.
75. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging. 2005; 4: 182-93.
76. Harada H, Kizaka-Kondoh S, Hiraoka M. Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1α containing Pro564. FEBS Lett. 2006; 580: 5718-22.
77. Harada H, Kizaka-Kondoh S, Li G et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene. 2007; 26: 7508-16.
78. Moeller BJ, Dreher MR, Rabbani ZN et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005; 8: 99-110.
79. Le QT. Identifying and targeting hypoxia in head and neck cancer: A brief overview of current approaches. Int J Radiat Oncol Biol Phys. 2007; 69: S56-8.
80. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA. 2007; 104: 5431-6.
81. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minshinton AI. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol. 2006; 78: 138-45.